Professor of Medicine
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, MD, USA
Baltimore, Maryland, United States
Ashraf Badros, MB. ChB.
Professor of Medicine
University of Maryland School of Medicine
Director, Multiple Myeloma Service
Greenebaum Comprehensive Cancer Center
Dr. Badros has extensive clinical experience in the diagnosis and management of multiple myeloma. He was a member of the Multiple Myeloma Research Institute at the University of Arkansas before moving to the University of Maryland, Greenebaum Cancer Center in 2001. His area of clinical research focuses on the novel agents and manipulation of the immune system to enhance anti-myeloma effects of various therapies. He was involved in the initial trails of thalidomide, lenalidomide and various proteasome inhibitors such as bortezomib. Carfilzomib, oprozomib and Marizomib. He has conducted seminal trails for transplantation of the elderly and patients with renal failure. He has conducted several trails for relapsed and refractory multiple myeloma focusing on novel agents’ combination with Bc1-2 antisense, histone deacetylase inhibitors, Cyclin D inhibitors (PD 0332991) and check point inhibitors (PD-1) and variousantibody trials (BI 505, elotuzumab, daratumumab). He defined risk factors of osteonecrosis of the jaw in multiple myeloma patients and received national institute of health funding for investigating its pathogenesis.
Dr. Badros has authored/coauthored over 160 publications appearing in peer-reviewed journals such as New England Journal of Medicine, Lancet Hematology, Lancet oncology, Blood, leukemia, Nature Medicine, the British Journal of Haematology, Transfusion, the Journal of Clinical Oncology, and the American Journal of Medicine. He authored 5 book chapters.
Disclosure information not submitted.
Friday, September 27, 2024
3:16 PM – 3:36 PM East Coast USA Time